This inventor holds 216 USPTO granted patents and 81 published patent applications and 48 EPO patents, primarily in Cardiac Neuromodulation (CPC class A61B18-1492). Top assignees: Medtronic Ardian Luxembourg S.a.r.l., Chf Solutions, Inc., Backbeat Medical, Inc.. Active years: 1990-2026.
Inventors with similar research interests:
Location History:
- Reisterstown, MD (US) (1990)
- Baltimore, MD (US) (1998 - 2006)
- New, NY (US) (2011)
- New York, NY (US) (2001 - 2024)
Company Filing History:
73 out of 236 
28 out of 45 
18 out of 47 
Years Active: 1990-2026
Areas of Expertise:
Title: Exploring the Innovations and Contributions of Mark Gelfand
Introduction:
In the dynamic world of medical innovation and patents, Mark Gelfand has made significant contributions through his numerous inventions. Hailing from New York, NY, Gelfand boasts an impressive number of 183 patents to his name. This article will delve into his latest patents, career highlights, and notable collaborations, shedding light on his invaluable contributions to the field of medical technology.
Latest Patents:
Gelfand's latest patents showcase his expertise in developing methods and devices to stimulate the heart and alleviate conditions like hypertension and heart failure. One of his recent patents involves a method and apparatus to stimulate the heart by increasing the secretion of endogenous atrial hormones. This method focuses on pacing the heart during the ventricular refractory period to induce premature atrial contraction without ventricular contraction. The pacing stimulates the atrial wall stress, peripheral vasodilation, and atrial natriuretic peptide (ANP) secretion, leading to potential therapeutic benefits for patients.
Another noteworthy patent from Gelfand involves methods and devices for endovascular ablation of a splanchnic nerve. This innovation targets the transvascular ablation of target tissues to treat conditions like heart failure and hypertension. Specifically, the patent describes the endovascular ablation of thoracic splanchnic nerves to increase venous capacitance and lower pulmonary blood pressure, offering potential treatment options for heart failure patients.
Career Highlights:
Throughout his career, Mark Gelfand has worked with various esteemed companies, leaving a lasting impact with his innovative ideas. Two notable companies he has been associated with include Medtronic Ardian Luxembourg S.a.r.l. and CHF Solutions Inc. (CardioMEMS). Medtronic Ardian Luxembourg S.a.r.l., now known as Medtronic, is a globally renowned medical technology company focused on developing therapies for a wide range of medical conditions. CHF Solutions Inc., known for its CardioMEMS technology, offers innovative solutions to monitor and manage patients with heart failure.
Collaborations:
Gelfand's passion for innovation extends beyond his own inventions, and he has collaborated with notable individuals in the field. Among his collaborators are Howard Levin and Hanson Gifford. Howard Levin is a prominent figure in the medical technology industry, known for his involvement with several successful medical device companies. Hanson Gifford, another collaborator of Gelfand, is recognized for his contributions to cardiovascular medicine and his role in founding the International Conference on Endovascular Intervention.
Conclusion:
Mark Gelfand's extensive patent portfolio and innovative contributions to medical technology have firmly established him as a key figure in the field. Through his inventions targeting heart conditions like hypertension and heart failure, Gelfand has paved the way for advancements that may enhance patient care and improve treatment outcomes. His collaborations with industry leaders further solidify his expertise and dedication to medical innovation. As we look to the future, we eagerly anticipate the potential impact of Gelfand's work on the advancement of healthcare technology.